<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title10.html">
                                    Title 10
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/10CFR35.html">Part 35
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 35.75  Release of individuals containing unsealed byproduct
                            </h3>
                            <p class="depth1"><em>(a)</em> A licensee may authorize the release from its control of any  individual who has been administered unsealed byproduct material or  implants containing byproduct material if the total   effective dose equivalent to any other individual from exposure to the  released individual is not likely to exceed 5 mSv (0.5 rem). \1\ ---------------------------------------------------------------------------</p><p class="depth2">\1\ The current revision of NUREG-1556, Vol. 9, ``Consolidated  Guidance About Materials Licenses: Program-Specific Guidance About  Medical Licenses'' describes methods for calculating doses to other  individuals and contains tables of activities not likely to cause doses  exceeding 5 mSv (0.5 rem). ---------------------------------------------------------------------------</p><p class="depth1"><em>(b)</em> A licensee shall provide the released individual, or the  individual's parent or guardian, with instructions, including written  instructions, on actions recommended to maintain doses to other  individuals as low as is reasonably achievable if the total effective  dose equivalent to any other individual is likely to exceed 1 mSv (0.1  rem). If the total effective dose equivalent to a nursing infant or  child could exceed 1 mSv (0.1 rem) assuming there were no interruption  of breast-feeding, the instructions must also include--</p><p class="depth2"><em>(1)</em> Guidance on the interruption or discontinuation of breast- feeding; and</p><p class="depth2"><em>(2)</em> Information on the potential consequences, if any, of failure to  follow the guidance.</p><p class="depth1"><em>(c)</em> A licensee shall maintain a record of the basis for authorizing  the release of an individual in accordance with Sec. 35.2075(a).</p><p class="depth1"><em>(d)</em> The licensee shall maintain a record of instructions provided to  a breast-feeding female in accordance with Sec. 35.2075(b).  [67 FR 20370, Apr. 24, 2002, as amended at 70 FR 16363, Mar. 30, 2005;  72 FR 45151, Aug. 13, 2007]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
